Q4'23 expectations
We forecast Q4 sales of SEK 33.5m, up 68% y-o-y from SEK 19.9m in Q4'22. OssDsign has already pre-announced sales for Oct-Nov (Dec 6, 2023) of SEK 25.2m, implying sales of SEK 9m in December in our Q4'23 forecast. The expected strong sales growth in Q4 is expected to have been driven by >230% sales growth for the Catalyst (orthobiologics) product to SEK 25m, from SEK 7.5m in Q4'22. We forecast Q4 adj. EBIT of -16.9m, excluding non-recurring items of SEK 15m related to the discontinuation of the CMF business during Q4'23.
Aktuellt
SENASTE
